ArticleInfection and immunity2008
Protective heterologous immunity against fatal ehrlichiosis and lack of protection following homologous challenge.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy and immunological correlates of an mRNA-LNP vaccine for protection against an emerging rickettsial pathogen.Emerging microbes & infections · 2026Article
- Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells.Immunological reviews · 2025Review
- Review: Protective Immunity and Immunopathology of Ehrlichiosis.Zoonoses (Shannon, Ireland) · 2022Article
- Memory and Memory-Like NK Cell Responses to Microbial Pathogens.Frontiers in cellular and infection microbiology · 2020Review
- Article
- Emerging Roles of Autophagy and Inflammasome in Ehrlichiosis.Frontiers in immunology · 2019Review
- NK Cell-Mediated Regulation of Protective Memory Responses against Intracellular Ehrlichial Pathogens.PloS one · 2016Article
- Type I interferon contributes to noncanonical inflammasome activation, mediates immunopathology, and impairs protective immunity during fatal infection with lipopolysaccharide-negative ehrlichiae.The American journal of pathology · 2015Article
- Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis.Infection and immunity · 2014Article
- Recombinant Ehrlichia P29 protein induces a protective immune response in a mouse model of ehrlichiosis.Vaccine · 2013Article
- Immunization with Ehrlichia P28 outer membrane proteins confers protection in a mouse model of ehrlichiosis.Clinical and vaccine immunology : CVI · 2011Article
- Molecular and cellular pathobiology of Ehrlichia infection: targets for new therapeutics and immunomodulation strategies.Expert reviews in molecular medicine · 2011Review
- Progress and obstacles in vaccine development for the ehrlichioses.Expert review of vaccines · 2010Review
- Human ehrlichiosis and anaplasmosis.Clinics in laboratory medicine · 2010Review
- Persistent infection contributes to heterologous protective immunity against fatal ehrlichiosis.Infection and immunity · 2009Article
- Strain and virulence diversity in the mouse pathogen Chlamydia muridarum.Infection and immunity · 2009Article
- Antigenic protein modifications in Ehrlichia.Parasite immunology · 2009Article
- Defining the immune response to Ehrlichia species using murine models.Veterinary parasitology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The roles of antibodies and memory T cells in protection against virulent Ehrlichia have not been completely investigated. In this study, we addressed these issues by using murine models of mild and fatal ehrlichiosis caused by related monocytotropic Ehrlichia strains. Mice were primed with either Ehrlichia muris or closely related virulent ehrlichiae transmitted by Ixodes ovatus (IOE) ticks given intraperitoneally or intradermally. All groups were reinfected intraperitoneally, 30 days later, with a lethal high dose of IOE. Priming with E. muris, but not IOE, induced strong CD4+ and CD8+ memory type 1 T-cell responses, Ehrlichia-specific immunoglobulin G (IgG) antibodies, and persistent infection. Compared to IOE-primed mice, subsequent lethal IOE challenge of E. muris-primed mice, resulted in (i) 100% protection against lethal infection, (ii) strong Ehrlichia-specific secondary gamma interferon (IFN-gamma)-producing effector/effector memory CD4+ and CD8+ T-cell responses, (iii) enhanced secondary anti-ehrlichial antibody response, (iv) accelerated bacterial clearance, and (v) the formation of granulomas in the liver and lung. E. muris-primed mice challenged with IOE had lower levels of serum interleukin-1alpha (IL-1alpha), IL-6, and IL-10 compared to unprimed mice challenged with IOE. Interestingly, the fatal secondary response in IOE-primed mice correlated with (i) decline in the Ehrlichia-specific CD4+ and CD8+ type 1 responses, (ii) marked hepatic apoptosis and necrosis, and (iii) substantial bacterial clearance, suggesting that fatal secondary response is due to immune-mediated tissue damage. In conclusion, protection against fatal ehrlichial infection correlates with strong expansion of IFN-gamma-producing CD4+ and CD8+ effector memory type 1 T cells, which appear to be maintained in the presence of IgG antibodies and persistent infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.